PF-Atlas › Clinical Trials › NCT06149793

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Empagliflozin · Phase 2

Registry ID

NCT06149793

Phase

Phase 2

Status

Active, not recruiting

Drug / intervention

Empagliflozin

Sponsor

University of Minnesota

Start

2024-01-08

About this trial

Empagliflozin is evaluated in NCT06149793, a Phase 2 idiopathic pulmonary fibrosis study sponsored by University of Minnesota. Current status: Active, not recruiting.

View NCT06149793 on ClinicalTrials.gov →

Explore related

All Empagliflozin trials All IPF trials

Related trials

Empagliflozin — NCT03151343

Medical disclaimer. This page summarizes public trial data for NCT06149793 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.